Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Bangladesh has been steadily growing in recent years due to various factors.
Customer preferences: Bangladesh is a developing country with a growing population, and as a result, there is an increasing demand for healthcare services. Cancer is a major health concern in the country, and the demand for oncology drugs has been on the rise. Patients and healthcare providers in Bangladesh prefer affordable and effective treatments, which has led to an increase in the demand for generic oncology drugs.
Trends in the market: The Oncology Drugs market in Bangladesh has been witnessing a shift towards the use of targeted therapies, which are more effective and have fewer side effects compared to traditional chemotherapy. This trend is driven by the increasing availability of targeted therapies in the country and the growing awareness among healthcare providers and patients about their benefits. Another trend in the market is the growing use of biosimilars, which are cheaper versions of biologic drugs used in cancer treatment.
Local special circumstances: Bangladesh has a large population, and a significant proportion of the population lives in poverty. As a result, the government has been taking steps to ensure that essential medicines, including oncology drugs, are affordable and accessible to all. The government has also been investing in the healthcare sector, which has led to an improvement in the overall healthcare infrastructure in the country.
Underlying macroeconomic factors: The Oncology Drugs market in Bangladesh is also influenced by macroeconomic factors such as the country's GDP growth, inflation rate, and exchange rate. The country's GDP has been growing steadily in recent years, which has led to an increase in the purchasing power of the population. However, the inflation rate in the country has also been high, which has made it difficult for some patients to afford expensive oncology drugs. The exchange rate of the Bangladeshi taka against major currencies such as the US dollar also affects the cost of imported oncology drugs in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
